HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Samikkannu, Thangavel ^a   Rao, Kurapati V K ^a   Salam, Abdul Ajees Abdul ^b   Atluri, Venkata S R ^a   Kaftanovskaya, Elena M ^a   Agudelo, Marisela ^a   Perez, Suray ^a   Yoo, Changwon ^c   Raymond, Andrea D ^a   Ding, Hong ^a   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b MANIPAL UNIVERSITY   (India)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; GLYCOPROTEIN GP 120; METHAMPHETAMINE;

AMINO ACID SEQUENCE; CELL CULTURE; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULAR GENETICS; NERVE CELL; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 4; CELLS, CULTURED; DOPAMINE AGONISTS; ENZYME INHIBITORS; GENE EXPRESSION; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; METHAMPHETAMINE; MOLECULAR SEQUENCE DATA; NEURONS; RECEPTORS, DOPAMINE D2; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84930966157     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11130     Document Type: Article

References (68)

1. Ensoli, F. et al. Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. J Immunol 162, 6268-6277 (1999).
2. Ferris, M. J., Mactutus, C. F. & Booze, R.M. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 32, 883-909 (2008).
3. Nath, A. et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14, 222-227 (2000).
4. Gonzalez-Scarano, F. & Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22, 219-40 (1999).
5. Koutsilieri, E. et al. Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm 109, 399-410 (2002).
6. Law, W. A. et al. Working memory in individuals with HIV infection. J Clin Exp Neuropsychol 16, 173-182 (1994).
7. Miller, E. N. et al. Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology 40, 197-203 (1990).
8. Wang, G. J. et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127, 2452-2458 (2004).
9. Chang, L., Alicata, D., Ernst, T & Volkow, N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 1, 16-32 (2007).
10. Wayman, G. A., Lee, Y. S., Tokumitsu, H., Silva, A & Soderling, T. R. Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron 59, 914-931 (2008).
11. Bastin, B., Payet, M. D. & Dupuis, G. Effects of modulators of adenylyl cyclase on interleukin-2 production, cytosolic Ca2+elevation, and K+ channel activity in Jurkat T cells. Cell Immunol 128, 385-389 (1990).
12. Cole, S. W., Jamieson, B. D. & Zack, J. A. cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J Immunol 162, 1392-1400 (1999).
13. Haraguchi, S., Good, R. A. & Day, N. K. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol Today 16, 595-603 (1995).
14. Brenneman, D. E., McCune, S. K., Mervis, R. F & Hill, J. M. gp120 as an etiologic agent for neuroAIDS: neurotoxicity and model systems. Adv Neuroimmunol 4, 157-165 (1994).
15. Galicia, O., Sanchez-Alavez, M., Mendez Diaz, M., Navarro, L. & Prospero-Garcia, O. HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia. Rev Invest Clin 54, 437-452 (2002).
16. Dreyer, E. B., Kaiser, P. K., Offermann, J. T & Lipton, S. A. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 248, 364-367 (1990).
17. Gee, K., Angel, J. B., Mishra, S., Blahoianu, M. A. & Kumar A. IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol 178, 798-807 (2007).
18. Kasahara, J., Fukunaga. K. & Miyamoto, E. Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca2+ /calmodulin-dependent protein kinases in cultured rat hippocampal neurons. J Biol Chem 274, 9061-9067 (1999).
19. Soderling, T. R., Chang, B. & Brickey, D. Cellular signaling through multifunctional Ca2+ /calmodulin-dependent protein kinase II. J Biol Chem 276, 3719-3722 (2001).
20. Darke, S., Kaye, S., McKetin, R. & Duflou, J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27, 253-262 (2008).
21. Homer, B. D. et al. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134, 301-310 (2008).
22. Lopez, O. L., Smith, G., Meltzer, C. C. & Becker, J. T. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry. Neuropsychol Behav Neurol 12, 184-192 (1999).
23. Nair, M. P. et al. Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J Neuroimmune Pharmacol 4, 129-139 (2004).
24. Nair, M. P. & Samikkannu, T. Differential regulation of neurotoxin in HIV clades: role of cocaine and methamphetamine. Cur HIV Res 10, 429-434 (2012).
25. Krasnova, I. N. et al. CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat. Neurobiol Dis 58, 132-143 (2013).
26. Goodwin, J. S. et al. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 284, 2978-2989 (2009).
27. Robertson, D. et al. HIV-1 nomenclature proposal. Science 288, 55-56 (2000).
28. Osmanov, S., Pattou, C., Walker, N., Schwardländer, B. & Esparza, J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29, 184-190 (2000).
29. Korber, B. T., MacInnes, K., Smith, R. F. & Myers, G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 68, 6730-6744 (1994).
30. Yang, W., Bielawski, J. P & Yang, Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol 57, 212-221 (2003).
31. Gnanakaran, S., et al. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81, 4886-4891 (2007).
32. Satishchandra, P. et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res 111, 14-23 (2000).
33. Letendre, S. Methamphetamine, HIV, and the Human Brain. The prn notebook 10, 13-17 (2005).
34. Gupta, S., et al. Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J Neurovirol 17, 239-47 (2011).
35. Suemaru, J., Akiyama, K., Tanabe, Y. & Kuroda, S. Methamphetamine decreases calcium-calmodulin dependent protein kinase II activity in discrete rat brain regions. Synapse 36, 155-166 (2000).
36. Semple, S. J., Patterson, T. L. & Grant, I. Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat 22, 149-56 (2002).
37. Samikkannu, T. et al. HIV infection and drugs of abuse: role of acute phase proteins. J Neuroinflammation 10, 113 (2013).
38. Substance Abuse and Mental Health Administration. National Survey on Drug Use and Health. (2013) Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.pdf. (Accessed: 13th January 2015).
39. Boddiger, D. Metamphetamine use linked to rising HIV transmission. Lancet 365, 1217-1218 (2005).
40. Silvers, J. M. et al. Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J Neurovirol 12, 140-145 (2006).
41. Eskandari, F. & Sternberg, E. M. Neural-immune interactions in health and disease. Ann NY Acad Sci 966, 20-27 (2002).
42. Basu, S. & Dasgupta, P. S. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102, 113-124 (2000).
43. Berger, J. R. & Nath, A. A careful neurologic examination should precede neuroimaging studies in HIV-infected patients with headache. Am J Neuroradiol 21, 441-442 (2000).
44. Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988-94 (2001).
45. Purohit, V., Rapaka, R. & Shurtleff, D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44, 102-10 (2011).
46. Chang, L. et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 42, 869-78 (2008).
47. Miyazaki, I., Asanuma, M., Diaz-Corrales, F. J., Miyoshi, K. & Ogawa, N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res 1029, 120-3 (2004).
48. Krasnova, I. N. & Cadet, J. L. Review Methamphetamine toxicity and messengers of death. Brain Res Rev 60, 379-407 (2009).
49. Larsson, M., Hagberg, L., Forsman, A. & Norkrans, G. Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28, 406-409 (1991).
50. Berger, J. R., Kumar, M., Kumar, A., Fernandez, J. B. & Levin, B. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8, 67-71 (1994).
51. Scott, J. C. et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17, 275-297 (2007).
52. Atluri, V. S., Kanthikeel, S. P., Reddy, V. B., Yndart, A. & Nair M. Human Synaptic Plasticity gene expression profile and dendritic spine density changes in HIV infected human neuronal cells: Role in HIV-associated neurocognitive disorders. PLoS One 8, e61399 (2013).
53. Mishra, M., Vetrivel, S., Siddappa, N. B., Ranga, U. & Seth P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 63, 366-376 (2008).
54. Rao V. R. et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 28, 10010-10016 (2008).
55. Samikkannu, T. et al. Differential regulation of indoleamine-2, 3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 25, 329-335 (2009).
56. Samikkannu, T. et al. Immuno-Neuropathogenesis of HIV-1 Clade B and C: Role of Redox Expression and Thiol Modification. Free Rad Med Biol 69, 136-144 (2014).
57. Samikkannu, T. et al. Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. J Neurovirol 17, 230-238 (2011).
58. Gupta, R. G., et al. HIV and SIV Induce Alterations in CNS CaMKII Expression and Activation: A Potential Mechanism for Cognitive Impairment. Am J Pathol 176, 2776-2784 (2010).
59. Page, G. et al. The up-regulation of the striatal dopamine transporter's activity by cAMP is PKA-, CaMK II- and phosphatase-dependent. Neurochem Int 45: 627-632 (2004).
60. Volkow, N.D. et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158, 2015-2021 (2001).
61. Choisy, M., Woelk, C. H., Guégan, J. F. & Robertson, D. L. A comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 78, 1962-1970 (2004).
62. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
63. Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996).
64. Tscherning, C. et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241, 181-188 (1998).
65. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
66. Huang, C. C. et al. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025-1028 (2005).
67. Pancera, M. et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 107, 1166-71 (2010).
68. Shively, C. A., Mirkes, S. J., Lu, N. Z., Henderson, J. A. & Bethea, C. L. Soy and social stress affect serotonin neurotransmission in primates. Pharmacogenomics J 3, 114-121 (2003).